Abstract
The treatment of cardiovascular disease in patients with diabetes has seen a sea change
in recent years with the development of novel antihyperglycemic agents. The impact
of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor
agonists (GLP-1 RAs), two medication classes introduced in the United States in the
wake of increased scrutiny by the US Food and Drug Administration on cardiovascular
disease and antihyperglycemic agents, highlight this progression. In recent trials,
SGLT2 inhibitors have demonstrated significant reductions in admissions for heart
failure in patients with established cardiovascular disease and those at risk of cardiovascular
disease, as well as significant reductions in major adverse cardiovascular events
for those with established cardiovascular disease. GLP-1 RAs have exhibited consistent
reductions in major adverse cardiovascular events for patients with established cardiovascular
disease. These developments have led the 2019 American Diabetes Association guidelines
to recommend considering each patient’s cardiovascular history when selecting antihyperglycemic
agents. The goal of this article is to review recent updates and provide relevant
strategies for providers on SGLT2 and GLP-1 RAs in treating cardiovascular disease
in patients with diabetes.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic and PersonalCorporate R&D ProfessionalsOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.Diabetes Res Clin Pract. 2017; 128: 40-50
- Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes.Diabetes Care. 2016; 39: 701-708https://doi.org/10.2337/dc152283
- Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC Study 30-year follow-up.Diabetes Care. 2016; 39: 686-693https://doi.org/10.2337/dc15-1990
- Intensive glucose control and macrovascular outcomes in type 2 diabetes.Diabetologia. 2009; 52: 2288-2298
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.Lancet. 2010; 376: 419-430
- Diabetes and cardiovascular disease: The Framingham Study.JAMA. 1979; 241: 2035-2038
- Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.Ann Intern Med. 2004; 141: 421-431
- Association of hemoglobin a1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk.Ann Intern Med. 2004; 141: 413-420
- Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med. 2007; 356: 2457-2471
- More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications.Clin Diabetes. 2016; 34: 173-180
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.Nat Rev Endocrinol. 2012; 8: 495-502
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences.Diab Vasc Dis Res. 2015; 12: 78-89
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.BMJ Open. 2012; 2: e001007
- Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? reflections from a Diabetes Care editors’ expert forum.Diabetes Care. 2018; 41: 14-31
- Canagliflozin and Cardiovascular and renal events in type 2 diabetes.N Engl J Med. 2017; 377: 644-657
- Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2019; 380 (Epub November 10, 2018): 347-357https://doi.org/10.1056/NEJMoa1812389
- Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs.Circulation. 2017; 136: 249-259
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet. 2019; 393: 31-39
- The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics.Am J Nephrol. 2017; 46: 462-472
- Novel therapies for diabetic kidney disease.Kid Int Suppl (2011). 2018; 8: 18-25
- Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.Eur Heart J. 2018; 39: 2368-2375
- Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2015; 373: 232-242
- Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2016; 375: 311-322
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med. 2016; 375: 1834-1844
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.Lancet. 2018; 392: 1519-1529
- HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?.Lancet. 2018; 392: 1489-1490
- Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.N Engl J Med. 2015; 373: 2247-2257
- Sodium glucose cotransporter-2 inhibition in heart failure.Circulation. 2017; 136: 1643-1658
- Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.J Clin Endocrinol Metab. 2003; 88: 3082-3089
- Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.Diabetes Obes Metab. 2018; 20: 42-49
- 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019.Diabetes Care. 2019; 42: S103
Article Info
Publication History
Published online: March 20, 2019
Footnotes
Funding: None.
Conflicts of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
